NCT05453539View on ClinicalTrials.gov

Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease

PHASE1TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

November 8, 2024

Study Completion Date

November 8, 2024

Conditions

Alzheimer Disease

Interventions

DRUG

DSPE-DOTA-Gd Liposomal Injection

Single dose, intravenous infusion

Trial Locations (2)

13353

CRS Clinical Research Services Berlin GmbH, Berlin

81377

LMU Klinikum, Munich

Sponsors

Lead Sponsor

Alzeca Biosciences, Inc.

All Listed Sponsors

collaborator

pharmtrace klinische Entwicklung GmbH

UNKNOWN

lead

Alzeca Biosciences, Inc.

INDUSTRY

NCT05453539 - Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Disease | Biotech Hunter | Biotech Hunter